Cell Genesys (CEGE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bosco who wrote (883)	4/25/2000 8:38:00 AM
From: david james	Read Replies (2) of 1298

Nice release. They made it clear this was not a gain in cash from an addition of shares. There were no milestone payments from Japanese Tobacco this quarter (usually about $4.5 mill). Could get one or two in May following the release of the phase II results announced at ASCO. JT is paying for the rights to the cancer vaccine in Europe. "Cell Genesys expects to receive approximately $45 million during the first two years of this collaboration." Will also be interesting to watch the Amgen/TKTX trial in May since CEGE will receive a cut in any revenues from TKTX's Epogen. This should at least generate revenues in Europe. The cash they have now should also generate $1 mill/month until they find a place to use it. Would love to know who they are talking with regarding the acquisition of a late stage profitable product.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next